Article
Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
Anticancer research - 1 Oct 2021
Fujimoto Naohiro, Harada Kenichi, Shiota Masaki, Tomisaki Ikko, Minato Akinori, Nagata Yujiro, Kimuro Rieko, Harada Mirii, Fujisawa Masato
Abstract excerpt
Remarkable developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC) have been achieved over the past decade. Although targeting the novel androgen receptor axis and using chemotherapeutic agents have improved survival, mCRPC is still a lethal disease. A better molecular characterization of cancer resulted in the determination of the important role of homologous recombination repair...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.